<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1561-3194</journal-id>
<journal-title><![CDATA[Revista de Ciencias Médicas de Pinar del Río]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Ciencias Médicas]]></abbrev-journal-title>
<issn>1561-3194</issn>
<publisher>
<publisher-name><![CDATA[Editorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1561-31942022000200022</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Características clínico epidemiológicas y manejo terapéutico del cáncer de riñón]]></article-title>
<article-title xml:lang="en"><![CDATA[Clinical-epidemiologic characteristics and therapeutic management of kidney cancer]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Suárez-Alfonso]]></surname>
<given-names><![CDATA[Oscar Eduardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castillo-García]]></surname>
<given-names><![CDATA[Idelma]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández-Campo]]></surname>
<given-names><![CDATA[Pedro Ricardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz-Dueñas]]></surname>
<given-names><![CDATA[Yaneisy]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Zayas-Veliz]]></surname>
<given-names><![CDATA[Reynaldo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Ciencias Médicas de Pinar del Río Hospital General Docente &#8220;Abel Santamaría Cuadrado&#8221; ]]></institution>
<addr-line><![CDATA[Pinar del Río ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Ciencias Médicas de Pinar del Río Hospital Clínico Quirúrgico Docente Dr. León Cuervo Rubio ]]></institution>
<addr-line><![CDATA[Pinar del Río ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2022</year>
</pub-date>
<volume>26</volume>
<numero>2</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1561-31942022000200022&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1561-31942022000200022&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1561-31942022000200022&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  el cáncer de riñón representa el 2 % de las neoplasias genitourinarias, habitualmente se diagnostican entre la cuarta y la sexta década de la vida.  Objetivo:  caracterizar el comportamiento clínico-epidemiológico, y manejo terapéutico del carcinoma de células renales en Pinar del Río entre el 2016-2019.  Métodos:  se realizó un estudio descriptivo, retrospectivo en Pinar del Río desde el 2016 al 2019, con un universo de 26 pacientes tratados por cirugía de cáncer renal y una muestra constituida por 21 pacientes atendidos en el Centro de atención Oncológico (III Congreso). Se recolectó la información de la historia clínica: edad, género y color de la piel, síntomas al diagnóstico, riñón afecto, etapas clínicas, histología y tratamiento. Se confeccionó una base de datos donde las variables cualitativas se expresaron en frecuencias absolutas y las relativas en porcientos.  Resultados:  hubo un predominio en el grupo de 70 años y más con ocho pacientes (33,3 %), en mayoría asintomáticos 12 (60 %), mayor afección del riñón izquierdo 15 (71,4 %) en parte media siete (33,3 %). Histológicamente, según el tipo de células claras 16 (76,2 %), diagnosticados 15 (71,4 %) en etapa I, con nefrectomía total 20 (95,2 %).  Conclusiones:  el cáncer renal predominó en la octava década de la vida, masculinos, asintomáticos al diagnóstico, más afección del riñón izquierdo en parte media. Histológicamente de acuerdo a células claras con grado nuclear II, sin invasión vascular ni linfática ni trombos en la vena renal, diagnosticados en etapa I, tratados con nefrectomía total en su mayoría.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  kidney cancer represents 2 % of genitourinary neoplasms; it is usually diagnosed between the fourth and sixth decade of life.  Objective:  to characterize the clinical-epidemiological behavior and therapeutic management of renal cell carcinoma in Pinar del Rio during 2016-2019.  Methods:  a descriptive, retrospective study was conducted in Pinar del Rio from 2016 to 2019, with a target group of 26 patients treated by renal cancer surgery and a sample comprising 21 patients who attended the Oncology Care Center (III Congreso). Clinical history information was collected: age, gender and skin color, symptoms at diagnosis, affected kidney, clinical stages, histology and treatment. A database was prepared where qualitative variables were expressed in absolute frequencies and relative frequencies in percentages.  Results:  there was a predominance in the age bracket 70 years and over with 8 patients (33,3 %), most of them asymptomatic 12 (60 %), with a greater involvement of the left kidney 15 (71,4 %) and 7 (33,3 %) in the middle part. Histologically corresponding to the clear cell type 16 (76,2 %), diagnosed 15 (71,4 %) in stage I, with total nephrectomy 20 (95,2 %).  Conclusions:  renal cancer predominated in the eighth decade of life, male, asymptomatic at diagnosis, with more involvement of the left kidney in the middle part. Histologically corresponding to clear cells with nuclear grade II, without vascular or lymphatic invasion or thrombi in the renal vein, diagnosed in stage I, mostly treated with total nephrectomy.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[CÁNCER]]></kwd>
<kwd lng="es"><![CDATA[RIÑÓN]]></kwd>
<kwd lng="es"><![CDATA[TUMOR]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Collaboration]]></surname>
<given-names><![CDATA[Global Burden of Disease Cancer]]></given-names>
</name>
<name>
<surname><![CDATA[Fitzmaurice]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Akinyemiju]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
<name>
<surname><![CDATA[Al Lami]]></surname>
<given-names><![CDATA[FH]]></given-names>
</name>
<name>
<surname><![CDATA[Alam]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Alizadeh-Navaei]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Systematic Analysis for the Global Burden of Disease Study.]]></article-title>
<source><![CDATA[JAMA Oncol.]]></source>
<year>2018</year>
<volume>4</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1553-68</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bazalytska]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
<name>
<surname><![CDATA[Persidsky]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Romanenko]]></surname>
<given-names><![CDATA[AM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#1052;&#1086;lecular mechanisms of initiation of carcinogenesis in the testis]]></article-title>
<source><![CDATA[ExpOncol]]></source>
<year>2019</year>
<volume>41</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>224-34</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Craven]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Vasudev]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
<name>
<surname><![CDATA[Banks]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Proteomics and the search for biomarkers for renal cáncer]]></article-title>
<source><![CDATA[ClinBiochem]]></source>
<year>2013</year>
<volume>46</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>456-65.</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anido Herranz]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[González Del alba]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<source><![CDATA[Cáncer renal]]></source>
<year>2019</year>
<publisher-name><![CDATA[SEOM]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García García]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Guerra Román]]></surname>
<given-names><![CDATA[FB]]></given-names>
</name>
<name>
<surname><![CDATA[García Morales]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enucleación simple en el tratamiento de los tumores renales]]></article-title>
<source><![CDATA[Rev. Cubana Urol]]></source>
<year>2017</year>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>13-24.</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sekar]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Patil]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Baum]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Pearl]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bausum]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bilen]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A novel preoperative inflammatory marker prognostic score in patients with localized and metastatic renal cell carcinoma]]></article-title>
<source><![CDATA[Asian Journal of Urology]]></source>
<year>2017</year>
<volume>4</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>230-8</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Turajlic]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Swanton]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Boshoff]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Kidney cancer: the next decade.]]></article-title>
<source><![CDATA[J ExpMed]]></source>
<year>2018</year>
<volume>215</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2477-9.</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gulley]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Rajan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Spigel]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Avelumab for patients with previously treated metastatic or recurrent non-smallcell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial]]></article-title>
<source><![CDATA[LancetOncol]]></source>
<year>2017</year>
<volume>18</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>599-610</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<source><![CDATA[NCCN guidelines: Kidney Cancer]]></source>
<year>2017</year>
<publisher-name><![CDATA[National Comprehensive Cancer Network]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<source><![CDATA[Anuario estadístico]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Cuba ]]></publisher-loc>
<publisher-name><![CDATA[Ministerio de Salud Pública]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González León]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Morera Pérez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Renal Cancer in theElderly]]></article-title>
<source><![CDATA[CurrUrolRep]]></source>
<year>2016</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>6</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sirohi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Agarwal]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Maughan]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities.]]></article-title>
<source><![CDATA[Res RepUrol]]></source>
<year>2018</year>
<volume>10</volume>
<page-range>205-17</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shingarev]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Jaimes]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Renal cell carcinoma: new insights and challenges for a clinician scientist]]></article-title>
<source><![CDATA[Am J Physiol Renal Physiol]]></source>
<year>2017</year>
<volume>313</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>145-54</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[ZJ]]></given-names>
</name>
<name>
<surname><![CDATA[Westphalen]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Zagoria]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CT and MRI of small renal masses.]]></article-title>
<source><![CDATA[Br J Radiol]]></source>
<year>2018</year>
<volume>91</volume>
<numero>1087</numero>
<issue>1087</issue>
<page-range>20180131</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ding]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Qin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical features and survival analysis of clear cell papillary renal cell carcinoma: A 10&#8209;year retrospective study from two institutions.]]></article-title>
<source><![CDATA[OncologyLetters]]></source>
<year>2018</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1010-22</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Acosta Jiménez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Jerónimo Guerrero]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Macías Clavijo]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Rivera Diez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández Briseño]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Beltrán Suárez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carcinoma de células renales: factores patológicos pronósticos, estadificación y clasificación histopatológica]]></article-title>
<source><![CDATA[Rev Med Inst Mex Seguro Soc]]></source>
<year>2015</year>
<volume>53</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>454-65</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Syed]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Shuch]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hereditary Kidney Cancer Syndromes and Surgical Management of the Small Renal Mass.]]></article-title>
<source><![CDATA[Urol Clin North Am]]></source>
<year>2017</year>
<volume>44</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>155-67</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rossi]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Klatte]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Usher&#8209;Smith]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Stewart]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology and screening for renal cáncer]]></article-title>
<source><![CDATA[World Journal of Urology]]></source>
<year>2018</year>
<volume>36</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1341-53</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bamias]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Escudier]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Sternberg]]></surname>
<given-names><![CDATA[CN]]></given-names>
</name>
<name>
<surname><![CDATA[Zagouri]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Dellis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Djavan]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation]]></article-title>
<source><![CDATA[Oncologist]]></source>
<year>2017</year>
<volume>22</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>667-79</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klapperich]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Jason Abel]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ziemlewicz]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Best]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lubner]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Nakada]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Percutaneous Microwave Ablation of Stage T1a Renal Cell Carcinoma: A Single-Center, Retrospective Study.]]></article-title>
<source><![CDATA[Radiology]]></source>
<year>2017</year>
<volume>284</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>272-80</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
